BR112022020742A2 - Anticorpo anti-ox40 e usos do mesmo - Google Patents

Anticorpo anti-ox40 e usos do mesmo

Info

Publication number
BR112022020742A2
BR112022020742A2 BR112022020742A BR112022020742A BR112022020742A2 BR 112022020742 A2 BR112022020742 A2 BR 112022020742A2 BR 112022020742 A BR112022020742 A BR 112022020742A BR 112022020742 A BR112022020742 A BR 112022020742A BR 112022020742 A2 BR112022020742 A2 BR 112022020742A2
Authority
BR
Brazil
Prior art keywords
antibody
same
antigen
treatment
conditions
Prior art date
Application number
BR112022020742A
Other languages
English (en)
Inventor
Yang Yizhen
Cai Yu
Li Xiong
Zhou Lei
Qing Weiguo
Su Wei-Guo
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of BR112022020742A2 publication Critical patent/BR112022020742A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

ANTICORPO ANTI-OX40 E USOS DO MESMO. A presente invenção provê um anticorpo anti-OX40 ou fragmento de ligação ao antígeno do mesmo, um método de preparação para o mesmo e o uso para o tratamento de doenças ou condições relacionadas a OX40.
BR112022020742A 2020-04-17 2021-04-16 Anticorpo anti-ox40 e usos do mesmo BR112022020742A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010304381 2020-04-17
PCT/CN2021/087617 WO2021209020A1 (en) 2020-04-17 2021-04-16 Anti-ox40 antibody and uses thereof

Publications (1)

Publication Number Publication Date
BR112022020742A2 true BR112022020742A2 (pt) 2022-12-20

Family

ID=78084656

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022020742A BR112022020742A2 (pt) 2020-04-17 2021-04-16 Anticorpo anti-ox40 e usos do mesmo
BR112022020741A BR112022020741A2 (pt) 2020-04-17 2021-04-16 Anticorpo anti-ox40 e usos do mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022020741A BR112022020741A2 (pt) 2020-04-17 2021-04-16 Anticorpo anti-ox40 e usos do mesmo

Country Status (15)

Country Link
US (2) US20230242657A1 (pt)
EP (2) EP4136116A1 (pt)
JP (2) JP2023523395A (pt)
KR (2) KR20230015328A (pt)
CN (2) CN115461366A (pt)
AR (2) AR121858A1 (pt)
AU (2) AU2021256799A1 (pt)
BR (2) BR112022020742A2 (pt)
CA (2) CA3175407A1 (pt)
CL (2) CL2022002829A1 (pt)
IL (2) IL297294A (pt)
MX (2) MX2022012913A (pt)
PE (2) PE20230255A1 (pt)
TW (2) TW202144423A (pt)
WO (2) WO2021209019A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968364A (zh) * 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
PE20211291A1 (es) * 2014-03-31 2021-07-20 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
US11046776B2 (en) * 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
BR112020010137A2 (pt) * 2017-11-24 2020-10-13 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-ox40 e usos dos mesmos
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
CA3100766A1 (en) * 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use

Also Published As

Publication number Publication date
KR20230015328A (ko) 2023-01-31
KR20230015327A (ko) 2023-01-31
US20230242657A1 (en) 2023-08-03
EP4136116A1 (en) 2023-02-22
CL2022002829A1 (es) 2023-06-09
CA3175413A1 (en) 2021-10-21
IL297294A (en) 2022-12-01
JP2023521475A (ja) 2023-05-24
CL2022002830A1 (es) 2023-06-09
CN115461366A (zh) 2022-12-09
EP4136117A4 (en) 2024-04-10
AU2021256799A1 (en) 2022-11-17
US20230151105A1 (en) 2023-05-18
PE20230255A1 (es) 2023-02-07
JP2023523395A (ja) 2023-06-05
PE20230682A1 (es) 2023-04-21
AR121857A1 (es) 2022-07-20
CN115461367A (zh) 2022-12-09
TW202144424A (zh) 2021-12-01
EP4136117A1 (en) 2023-02-22
MX2022012913A (es) 2022-11-14
AU2021256226A1 (en) 2022-11-17
WO2021209020A1 (en) 2021-10-21
CA3175407A1 (en) 2021-10-21
AR121858A1 (es) 2022-07-20
MX2022012915A (es) 2022-11-16
BR112022020741A2 (pt) 2022-12-20
WO2021209019A1 (en) 2021-10-21
IL297292A (en) 2022-12-01
TW202144423A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112019002282A2 (pt) anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CL2022000030A1 (es) Moléculas de unión a claudina-6 y usos de las mismas
MX2018012473A (es) Agentes que reconocen el epitopo de clever-1 y usos de los mismos.
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112017002433A2 (pt) anticorpos anticeramida
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
BR112022021641A2 (pt) Tratamento de combinação de anticorpos anti-cd40 para câncer
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
BR112022014487A2 (pt) Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo
CL2022002727A1 (es) Anticuerpo anti-cd47 y usos del mismo
BR112022020741A2 (pt) Anticorpo anti-ox40 e usos do mesmo
BR112022009265A2 (pt) Método de tratamento do câncer e método para aumentar, potencializar ou estimular uma resposta ou função imune
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
MX2021000235A (es) Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.
EA202192695A1 (ru) Комбинации ингибиторов транскрипции и ингибиторов иммунных контрольных точек для лечения заболевания